Cargando…

Never too old to fight breast cancer: A case report

RATIONALE: Breast cancer is the most common cancer affecting females worldwide and its lifetime risk increases with age. Human epidermal growth factor receptor gene-2 (HER-2) positive breast cancer represents about 20% of all breast cancers, 1 out of 10 is diagnosed in women over 70 years of age. It...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuradelli, Monica, Masci, Giovanna, Ferraro, Emanuela, Losurdo, Agnese, De Sanctis, Rita, Torrisi, Rosalba, Santoro, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851756/
https://www.ncbi.nlm.nih.gov/pubmed/29489698
http://dx.doi.org/10.1097/MD.0000000000009981
_version_ 1783306450540429312
author Zuradelli, Monica
Masci, Giovanna
Ferraro, Emanuela
Losurdo, Agnese
De Sanctis, Rita
Torrisi, Rosalba
Santoro, Armando
author_facet Zuradelli, Monica
Masci, Giovanna
Ferraro, Emanuela
Losurdo, Agnese
De Sanctis, Rita
Torrisi, Rosalba
Santoro, Armando
author_sort Zuradelli, Monica
collection PubMed
description RATIONALE: Breast cancer is the most common cancer affecting females worldwide and its lifetime risk increases with age. Human epidermal growth factor receptor gene-2 (HER-2) positive breast cancer represents about 20% of all breast cancers, 1 out of 10 is diagnosed in women over 70 years of age. It tends to be more aggressive and to spread more quickly than other subtypes, but the introduction in clinical practice of new anti-HER-2 agents combined with chemotherapy has significantly improved progression free and overall survival. Elderly patients are frequently undertreated because of concerns about their age, performance status, and comorbidities. Here, we report a case of an octogenarian patient treated with T-DM1 with brilliant results. PATIENT CONCERNS: An 87 years old woman affected with HER-2 positive breast cancer presented progression of disease with lymph node and skin metastases after 3 lines of chemoimmunotherapy. DIAGNOSES: Breast cancer in elderly patient, lymph node, and skin metastases. INTERVENTIONS: Chemoimmunotherapy (trastuzumab emtansine). OUTCOME: Objective response of the disease and significant clinical benefit. LESSONS: This case clearly suggests that age and comorbidities do not always represent an absolute contraindication to combined treatments.
format Online
Article
Text
id pubmed-5851756
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-58517562018-03-21 Never too old to fight breast cancer: A case report Zuradelli, Monica Masci, Giovanna Ferraro, Emanuela Losurdo, Agnese De Sanctis, Rita Torrisi, Rosalba Santoro, Armando Medicine (Baltimore) 5700 RATIONALE: Breast cancer is the most common cancer affecting females worldwide and its lifetime risk increases with age. Human epidermal growth factor receptor gene-2 (HER-2) positive breast cancer represents about 20% of all breast cancers, 1 out of 10 is diagnosed in women over 70 years of age. It tends to be more aggressive and to spread more quickly than other subtypes, but the introduction in clinical practice of new anti-HER-2 agents combined with chemotherapy has significantly improved progression free and overall survival. Elderly patients are frequently undertreated because of concerns about their age, performance status, and comorbidities. Here, we report a case of an octogenarian patient treated with T-DM1 with brilliant results. PATIENT CONCERNS: An 87 years old woman affected with HER-2 positive breast cancer presented progression of disease with lymph node and skin metastases after 3 lines of chemoimmunotherapy. DIAGNOSES: Breast cancer in elderly patient, lymph node, and skin metastases. INTERVENTIONS: Chemoimmunotherapy (trastuzumab emtansine). OUTCOME: Objective response of the disease and significant clinical benefit. LESSONS: This case clearly suggests that age and comorbidities do not always represent an absolute contraindication to combined treatments. Wolters Kluwer Health 2018-03-02 /pmc/articles/PMC5851756/ /pubmed/29489698 http://dx.doi.org/10.1097/MD.0000000000009981 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-No Derivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 5700
Zuradelli, Monica
Masci, Giovanna
Ferraro, Emanuela
Losurdo, Agnese
De Sanctis, Rita
Torrisi, Rosalba
Santoro, Armando
Never too old to fight breast cancer: A case report
title Never too old to fight breast cancer: A case report
title_full Never too old to fight breast cancer: A case report
title_fullStr Never too old to fight breast cancer: A case report
title_full_unstemmed Never too old to fight breast cancer: A case report
title_short Never too old to fight breast cancer: A case report
title_sort never too old to fight breast cancer: a case report
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851756/
https://www.ncbi.nlm.nih.gov/pubmed/29489698
http://dx.doi.org/10.1097/MD.0000000000009981
work_keys_str_mv AT zuradellimonica nevertoooldtofightbreastcanceracasereport
AT mascigiovanna nevertoooldtofightbreastcanceracasereport
AT ferraroemanuela nevertoooldtofightbreastcanceracasereport
AT losurdoagnese nevertoooldtofightbreastcanceracasereport
AT desanctisrita nevertoooldtofightbreastcanceracasereport
AT torrisirosalba nevertoooldtofightbreastcanceracasereport
AT santoroarmando nevertoooldtofightbreastcanceracasereport